A robust and quantitative method for tracking liposome contents after intravenous administration

Journal of Controlled Release

Volumn 176, Issue 1, 2014, Pages 86-93

  Kohli, Aditya G ^a,b   Kieler Ferguson, Heidi M ^a   Chan, Darren ^b   Szoka, Francis C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

4 methylumbelliferone; Drug release; Liposomes; Sterol modified lipids

Indexed keywords

4-METHYLUMBELLIFERONE; CONTENTS DELIVERIES; CONTENTS RELEASE; DRUG RELEASE; FLUORESCENCE SPECTRA; INTRAVENOUS ADMINISTRATION; QUANTITATIVE METHOD; TISSUE DISTRIBUTIONS;

ALCOHOLS; CHOLESTEROL; DRUG THERAPY; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPOSOMES; PHOSPHOLIPIDS;

TISSUE;

4 METHYLUMBELLIFERYL PHOSPHATE; LIPOSOME; PHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; CONFORMATION; DRUG DISTRIBUTION; ENCAPSULATION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; LIPID BILAYER; MEMBRANE FLUIDITY; MEMBRANE STABILIZATION; NONHUMAN; PHASE TRANSITION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; TISSUE DISTRIBUTION;

4-METHYLUMBELLIFERONE; DRUG RELEASE; LIPOSOMES; STEROL-MODIFIED LIPIDS;

ADMINISTRATION, INTRAVENOUS; ANIMALS; FLUORESCENT DYES; HYMECROMONE; LIPIDS; LIPOSOMES; LIVER; MICE; SERUM; SPECTROMETRY, FLUORESCENCE; SPLEEN; TISSUE DISTRIBUTION;

EID: 84892622174     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.12.014     Document Type: Article

References (34)

1. W.C. Zamboni, A.C. Gervais, M.J. Egorin, J.H.M. Schellens, E.G. Zuhowski, and D. Pluim et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma Cancer Chemother. Pharmacol. 53 2004 329 336
2. D.C. Drummond, C.O. Noble, M.E. Hayes, J.W. Park, and D.B. Kirpotin Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development J. Pharm. Sci. 97 2008 4696 4740
3. Y.-E. Rahman, and B.J. Wright Liposomes containing chelating agents. Cellular penetration and a possible mechanism of metal removal J. Cell Biol. 65 1975 112 122
4. A.M. Thomas, A.I. Kapanen, J.I. Hare, E. Ramsay, K. Edwards, and G. Karlsson et al. Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy J. Control. Release 150 2011 212 219
5. K.J. Harrington, S. Mohammadtaghi, P.S. Uster, D. Glass, A.M. Peters, and R.G. Vile et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes Clin. Cancer Res. 7 2001 243 254
6. A.S. Rudolph, R.W. Klipper, B. Goins, and W.T. Phillips In vivo biodistribution of a radiolabeled blood substitute: 99mTc-labeled liposome-encapsulated hemoglobin in an anesthetized rabbit Proc. Natl. Acad. Sci. U. S. A. 88 1991 10976 10980
7. A. Gabizon, J. Hliberty, R.M. Straubinger, D.C. Price, and D. Papahadjopoulos an improved method for in vivo tracing and imaging of liposomes using a gallium 67-deferoxamine complex J. Liposome Res. 1 1988 123 135
8. R.M. Abra, H. Schreier, and F.C. Szoka The use of a new radioactive-iodine labeled lipid marker to follow in vivo disposition of liposomes: comparison with an encapsulated aqueous space marker Res. Commun. Chem. Pathol. Pharmacol. 37 1982 199 213
9. E. Claassen Post-formation fluorescent labelling of liposomal membranes. In vivo detection, localisation and kinetics J. Immunol. Methods 147 1992 231 240
10. D.K. Struck, D. Hoekstra, and R.E. Pagano Use of resonance energy transfer to monitor membrane fusion Biochemistry 20 1981 4093 4099
11. J. Damen, J. Regts, and G. Scherphof Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high density lipoproteins. Dependence on cholesterol content and phospholipid composition Biochim. Biophys. Acta 665 1981 538 545
12. J.N. Weinstein, S. Yoshikami, P. Henkart, R. Blumenthal, and W.A. Hagins Liposome-cell interaction: transfer and intracellular release of a trapped fluorescent marker Science 195 1977 489 492
13. F. Perche, N.R. Patel, and V.P. Torchilin Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model J. Control. Release 164 2012 95 102
14. T. Roy Chaudhuri, R.D. Arnold, J. Yang, S.G. Turowski, Y. Qu, and J.A. Spernyak et al. Mechanisms of tumor vascular priming by a nanoparticulate doxorubicin formulation Pharm. Res. 29 2012 3312 3324
15. N.Z. Wu, R.D. Braun, M.H. Gaber, G.M. Lin, E.T. Ong, and S. Shan et al. Simultaneous measurement of liposome extravasation and content release in tumors Microcirculation 4 1997 83 101
16. H. Ellens, J. Bentz, and F.C. Szoka Proton-and calcium-induced fusion and destabilization of liposomes Biochemistry 24 1985 3099 3106
17. A. Schroeder, R. Honen, K. Turjeman, A. Gabizon, J. Kost, and Y. Barenholz Ultrasound triggered release of cisplatin from liposomes in murine tumors J. Control. Release 137 2009 63 68
18. K.M. Laginha, S. Verwoert, G.J.R. Charrois, and T.M. Allen Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors Clin. Cancer Res. 11 2005 6944 6949
19. T. Tippayamontri, R. Kotb, B. Paquette, and L. Sanche Cellular uptake and cytoplasm/DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116 Invest. New Drugs 29 2011 1321 1327
20. M.R. Mauk, R.C. Gamble, and J.D. Baldeschwieler Targeting of lipid vesicles: specificity of carbohydrate receptor analogues for leukocytes in mice Proc. Natl. Acad. Sci. U. S. A. 77 1980 4430 4434
21. F.C. Szoka Jr., and C.S. Jones Uptake of liposome-encapsulated agents Methods Enzymol. 149 1987 143 147
22. H.N. Fernley, and P.G. Walker Kinetic behaviour of calf-intestinal alkaline phosphatase with 4-methylumbelliferyl phosphate Biochem. J. 97 1965 95 103
23. Z. Huang, M.R. Jaafari, and F.C. Szoka Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery Angew. Chem. Int. Ed. Engl. 48 2009 4146 4149
24. Z. Huang, and F.C. Szoka Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties J. Am. Chem. Soc. 130 2008 15702 15712
25. R. Vest, R. Wallis, L.B. Jensen, A.C. Haws, J. Callister, and B. Brimhall et al. Use of steady-state laurdan fluorescence to detect changes in liquid ordered phases in human erythrocyte membranes J. Membr. Biol. 211 2006 15 25
26. G.M. van Kempen, and G.S. Jansen Quantitative determination of phenolsulfotransferase using 4-methylumbelliferone Anal. Biochem. 46 1972 438 442
27. J.M. Denu, D.L. Lohse, J. Vijayalakshmi, M.A. Saper, and J.E. Dixon Visualization of intermediate and transition-state structures in protein-tyrosine phosphatase catalysis Proc. Natl. Acad. Sci. U. S. A. 93 1996 2493 2498
28. B.R. Lentz Use of fluorescent probes to monitor molecular order and motions within liposome bilayers Chem. Phys. Lipids 64 1993 99 116
29. E.R. Garrett, J. Venitz, K. Eberst, and J.J. Cerda Pharmacokinetics and bioavailabilities of hymecromone in human volunteers Biopharm. Drug Dispos. 14 1993 13 39
30. T.M. Allen, D.R. Mumbengegwi, and G.J.R. Charrois Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates Clin. Cancer Res. 11 2005 3567 3573
31. D.C. Drummond, C.O. Noble, Z. Guo, M.E. Hayes, C. Connolly-Ingram, and B.S. Gabriel et al. Development of a highly stable and targetable nanoliposomal formulation of topotecan J. Control. Release 141 2010 13 21
32. C.A. Alabi, K.T. Love, G. Sahay, H. Yin, K.M. Luly, and R. Langer et al. Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery Proc. Natl. Acad. Sci. U. S. A. 110 2013 12881 12886
33. L.D. Mayer, L.C. Tai, D.S. Ko, D. Masin, R.S. Ginsberg, and P.R. Cullis et al. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice Cancer Res. 49 1989 5922 5930
34. E.S. Kim, C. Lu, F.R. Khuri, M. Tonda, B.S. Glisson, and D. Liu et al. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer Lung Cancer 34 2001 427 432